Macrophages are recruited to hypoxic tumor areas and acquire a Pro-Angiogenic M2-Polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin

Oncotarget

Volumn 5, Issue 14, 2014, Pages 5350-5368

  Tripathi, Chakrapani ^a,b   Tewari, Brij Nath ^c   Kanchan, Ranjana Kumari ^a   Baghel, Khemraj Singh ^a   Nautiyal, Naveen ^a   Shrivastava, Richa ^a,b   Kaur, Harbeer ^a   Bramha Bhatt, Madan Lal ^c   Bhadauria, Smrati ^a,b  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

^c KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Breast Cancer; Chemoattract; Hypoxia; M2 Polarization; Pro angiogenic; TAM; Tumor microenvironment

Indexed keywords

BEVACIZUMAB; EOTAXIN; ONCOSTATIN M;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CELL HOMING; CELL HYPOXIA; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; M2 MACROPHAGE; MACROPHAGE; MEDIATOR RELEASE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; EXPERIMENTAL MAMMARY NEOPLASM; MCF 7 CELL LINE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CHEMOKINE CCL11; FEMALE; HUMANS; MACROPHAGES; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELLS; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; ONCOSTATIN M; PHENOTYPE; RANDOM ALLOCATION; TUMOR MICROENVIRONMENT;

EID: 84906280651     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2110     Document Type: Article

References (56)

1. Sica A, Schioppa T, Mantovani A, and Altadena P. Tumor-associated macrophages are a distinct M2 polarized population promoting tumor progression: potential targets of anti-cancer therapy. Eur. J. Cancer. 2006 ;42:717-727.
2. Mueller MM, and Fusing NE. Friends or foes-bipolar effects of the tumor stoma in cancer. Nat. Rev. Cancer. 2004; 4:839-849.
3. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C, and Tabar V. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010; 468:829-833.
4. Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, Di SC, Naldini L, De PM, Tozer GM, and Lewis CE. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J. Clin. Invest. 2011; 121, 1969-1973.
5. Bingle L, Brown NJ, and Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 2002; 196:254-265.
6. Zhang BC, Gao J, Wang J, Rao ZG, Wang BC, and Gao JF. Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med. Oncol. 2011; 28:1447-1452.
7. Negus RPM, Stamp GWH, Hadley J, Balkwill FR. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol. 1997;150:1723-1734
8. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA. et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011; 1:54-67.
9. De,P M, Murdoch C, Venneri MA, Naldini L, and Lewis CE. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol. 2007; 28:519-524.
10. Mantovani A, Allavena P, Sica A, and Balkwill F. Cancer-related inflammation. Nature 2008;454:436-444
11. Grivennikov SI, Greten FR, and Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140:883-899.
12. Qian BZ, and Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141:39-51.
13. Hanahan D, and Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21:309-322.
14. Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, Shono Y, Kitabatake M, Kakimi K, Mukaida N. et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood. 2008; 111:5457-5466.
15. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, Mack M, Pipeleers D, In't VP, De BP. et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010; 70:5728-5739.
16. Cortez-Retamozo V, Etzrodt M, Newton A, Rauch PJ, Chudnovskiy A, Berger C, Ryan RJ, Iwamoto Y, Marinelli B, Gorbatov R, et al. Origins of tumor-associated macrophages and neutrophils. Proc. Natl.Acad. Sci. USA 2012; 109: 2491-2496.
17. Lin EY, Nguyen AV, Russell RG, and Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 2001; 193:727-740.
18. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, and Balkwill FR. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res. 2003; 63:8360-8365.
19. Gordon S, and Taylor PR. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005; 5:953-964.
20. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol. 2011; 11(11):750-61. doi: 10.1038/nri3088.
21. Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, Pottorf BJ, Nitz MD, Richards WG, Sugarbaker DJ. et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am. J. Pathol. 2005; 166:1827-1840.
22. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, and Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25:677-686.
23. De PM, and Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 2013; 23:277-286.
24. Pola C, Formenti SC, and Schneider RJ. Vitronectin-alphavbeta3 integrin engagement directs hypoxia-resistant mTOR activity and sustained protein synthesis linked to invasion by breast cancer cells. Cancer Res. 2013; 73:4571-4578.
25. Nafiseh Pakravan. Tumorigenesis: cell defense against hypoxia? Oncology Reviews. 2013;7:e1
26. Duffy JP, Eibl G, Reber HA, and Hines OJ. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol. Cancer. 2003; 2:12.
27. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT, Jeffrey SS, and Giaccia AJ. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006; 440:1222-1226.
28. Murdoch C, Giannoudis A, and Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood. 2004; 104:2224-2234.
29. Biswas SK, Sica A, and Lewis CE. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J.Immunol. 2008; 180:2011-2017.
30. Ohno S, Ohno Y, Suzuki N, Kamei T, Koike K, Inagawa H, Kohchi C, Soma G, and Inoue M. Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res. 2004; 24:3335-3342.
31. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, and Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996; 56:4625-4629.
32. Leek RD, Landers RJ, Harris AL, and Lewis CE. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br. J. Cancer. 1999; 79:991-995.
33. Burton JL, Oakley N, and Anderson JB. Recent advances in the histopathology and molecular biology of prostate cancer. BJU. Int. 2000; 85:87-94.
34. Negus RPM, Stamp GWH, Hadley J, Balkwill FR. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol. 1997;150:1723-1734
35. Green CE, Liu T, Montel V, Hsiao G, Lester RD, Subramaniam S, Gonias SL, and Klemke RL. Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization. PLoS One. 2009; 4:e6713.
36. Lin EY, Nguyen AV, Russell RG, and Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp.Med.2001; 193:727-740.
37. Zhang BC, Gao J, Wang J, Rao ZG, Wang BC, and Gao JF. Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med. Oncol. 2011; 28:1447-1452.
38. Lewis CE, Leek R, Harris A, and McGee JO. Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J. Leukoc. Biol. 1995; 57:747-751.
39. David C S, Christine K, Yanxia L, Damu T, Carl D R. Oncostatin M induction of eotaxin-1 expression requires the convergence of PI3'K and ERK1/2 MAPK signal transduction pathways. Cellular Signaling. 2008; 20: 1142-1150
40. Folkman J and Shing Y. Angiogenesis. J. Biol. Chem. 1992; 267:10931-10934.
41. Helmlinger G, Netti PA, Lichtenbeld HC, Melder RJ, Jain RK. Solid stress inhibits the growth of multispheroid tumors. Nature Biotechnology. 1997; 15:778-783.
42. Park JE ,Tan HS, Datta A, Lai RC, Zhang H, Meng W, Lim SK, Sze S K. Hypoxic Tumor Cell Modulates Its Microenvironment to Enhance Angiogenic and Metastatic Potential by Secretion of Proteins and Exosomes.Mol Cell Proteomics. 2010;9(6): 1085-1099
43. Lewis CE, and Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006; 66:605-612.
44. Alicia A, Christina D, Eleni V, Yeny Martinez de la T, Katerina V, Eleni D L., Eleftheria I et al. Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. PNAS. 2012;109 24: 9517-9522.
45. Zoltan A, Shi-Yin F, Yanhong M, Jorge L. R, Archana Bommi-R, Geoffrey G, Marcus Cooper, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α. NATURE. 2008;451: doi:10.1038/nature06613.
46. Nabendu P, Shuang, L, Hui-Kuo S, Bin, L, Daphne Haas-K, David S. et al. Sp1 Is Involved in Akt-mediated Induction of VEGF Expression through an HIF-1-independent Mechanism. Molecular Biology of the Cell. 2004;15: 4841-4853.
47. Bergers G. and Hanahan,D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer. 2008; 8: 592-603.
48. Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS, Papadopoulos N, Kyle AH, Minchinton AI, Yancopoulos GD, and Thurston G. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013; 73: 108-118.
49. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L, and De PM. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell. 2011; 19: 512-526
50. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, and Condeelis J. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004; 64:7022-7029.
51. Zhang W, Zhu X, Sun H, Xiong Y, Zhuang P, Xu H, Kong L, Wang L, Wu W, Tang Z. Depletion of Tumor-Associated Macrophages Enhances theEffect of Sorafenib in Metastatic Liver Cancer Models by Anti-metastatic and Anti-angiogenic Effects. Clin Cancer Res. 2010;16:3420-3430.
52. Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, Johnson M, Lusis AJ, Cohen DA, Iruela-Arispe ML, and Wu L. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of anti-angiogenic therapy. Blood. 2010; 115: 1461-1471.
53. Daigneault M, Preston JA, Marriott HM, Whyte MK, and Dockrell DH. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS One. 2010; 5:e8668.
54. Bouhlel M.A, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N. et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007; 6:137-143.
55. Pfaffl M W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research. 2001; 29: No. 9 00.
56. Lowry O H, Nira J R, A Lewis F, and Rose J R. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951; 193: 265-275.